The Plasma Cell Neoplasm drugs in development market research report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Plasma Cell Neoplasm. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Plasma Cell Neoplasm and features dormant and discontinued products.
GlobalData tracks 450 drugs in development for Plasma Cell Neoplasm by 346 companies/universities/institutes. The top development phase for Plasma Cell Neoplasm is preclinical with 235 drugs in that stage. The Plasma Cell Neoplasm pipeline has 388 drugs in development by companies and 62 by universities/ institutes. Some of the companies in the Plasma Cell Neoplasm pipeline products market are: Bristol-Myers Squibb, Shenzhen Geno-Immune Medical Institute and Johnson & Johnson.
The key targets in the Plasma Cell Neoplasm pipeline products market include Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17), Cells Expressing ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′ Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase or ADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20), and CD3 .
The key mechanisms of action in the Plasma Cell Neoplasm pipeline product include Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17) with 60 drugs in Phase III. The Plasma Cell Neoplasm pipeline products include 16 routes of administration with the top ROA being Intravenous and 21 key molecule types in the Plasma Cell Neoplasm pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Plasma Cell Neoplasm overview
Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some etiological factors. Immunoglobulin test, biopsy, blood and urine analysis, radiographic findings CT scan, MRI are diagnostic approaches. Multiple Myeloma is classified into three stages. Immunotherapy, targeted therapy, chemotherapy, combination therapy, surgical and radiation therapy are common treatment approaches for treating plasma cell cancers.
For a complete picture of Plasma Cell Neoplasm’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
